Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea
Therapeutic Innovation & Regulatory Science · 2024
DOI: 10.1007/s43441-024-00661-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2024. Verfasst von Joo Hee Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Strategy Center for Combination Products (RSCP), Ajou University, Suwon, 16499, Republic of Korea. elisekim@ajou.ac.kr. Hauptthemen laut MEDLINE: Device Approval. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Combination products (CPs) combine two or more product types such as drugs, devices, and/or biological products for increased safety and clinical effectiveness. The emergence of innovative CPs poses new challenges for regulatory agencies in assigning jurisdiction for premarket review and oversight. In US, the 1990 Safe Medical Devices Act defines and provides classification criteria for CPs, and the US government has developed a regulatory process through multiple acts, including the 21st Century Cures Act of 2016. Meanwhile, regulators in the European Union (EU) and the Republic of Korea have recently recognized the importance of premarket pathways for CPs. The European Medicines Agency (EMA) has issued guidelines and explanations on compliance issues related to drug-device CPs under MDR. EMA doesn't have the definitions of CPs, but uses the term drug-device combination products (drug-device CPs). CPs are categorized as drugs or medical devices, which follow their relevant regulatory framework. The Ministry of Food and Drug Safety (MFDS) in Korea has legal definitions of CPs under the Notice of the MFDS. CPs are designated as drugs or medical devices according to their primary mode of actions (PMOA) and follow regulatory processes through the framework of drugs or medical devices. This study aims to comprehensively summarize the regulatory oversight of CPs by analyzing the regulatory policies and legal frameworks in the US, the EU, and Korea. The regulatory challenges encountered when developing CPs are also discussed. With specific emphasis on the combination of drugs and devices, this study provides in-depth insights into the regulatory landscape, shedding light on the unique challenges associated with the development of CPs for this particular intersection of drugs and devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regulatory Strategy Center for Combination Products (RSCP), Ajou University, Suwon, 16499, Republic of Korea. elisekim@ajou.ac.kr.
- Regulatory Strategy Center for Combination Products (RSCP), Ajou University, Suwon, 16499, Republic of Korea.
ORCID-Profile: Joo Hee Kim
Förderung
- Ministry of Food and Drug Safety
Zitieren
APA
Kim, J. H., Kwon, S., Seol, J. E., Kim, M. H., & Kim, S. D. (2024). Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-024-00661-2
Vancouver
Kim JH, Kwon S, Seol JE, Kim MH, Kim SD. Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea. Therapeutic Innovation & Regulatory Science. 2024. doi:10.1007/s43441-024-00661-2
BibTeX
@article{Kim2024,
author = {Kim, Joo Hee and Kwon, Sera and Seol, Ju Eun and Kim, Mi Hye and Kim, Su Dong},
title = {Regulatory Framework for Drug-Device Combination Products in the United States, Europe, and Korea},
journal = {Therapeutic Innovation & Regulatory Science},
year = {2024},
doi = {10.1007/s43441-024-00661-2}
}
EUVIMED